FDA Approval: Zidesamtinib and ROS1 NSCLC

Lung Cancer Considered by Lung Cancer Considered

Patients with ROS1-positive NSCLC have a new treatment option following the FDA approval of zidesamtinib for those previously treated with a ROS1 tyrosine kinase inhibitor. In this episode, Dr. Stephen Liu, Dr. Alexander...View more